Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
SEATTLE, April 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ) announced today that it will present data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver, April 1...
Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
JERUSALEM, March 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals,
Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery
systems, announced today that it has been selected to present the results
from the study, entitled, "Open Label Study to Assess the Safety,
Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
RICHMOND, Calif., March 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business ...
Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
WAYNE, N.J., Dec. 5 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data on Campath(R) (alemtuzumab) and Leukine(R) (sargramostim) will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH) from December 6-9, 2008 in San Francisco, Californi...
Genmab Announces Upcoming Ofatumumab Studies
Front Line CLL, NHL and CLL Retreatment and Japanese Development Studies Planned
COPENHAGEN, Denmark, August 25 /PRNewswire-FirstCall/ -- Genmab has
announced plans to begin four studies of ofatumumab in chronic lymphocytic
leukemia and non-Hodgkin's lymphoma.
Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.
("Rib-X" or the "Company"), a development-stage company focused on the
discovery and development of novel antibiotics for the treatment of
antibiotic-resistant infections, announced today that company
representatives are givi...
Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ -- Pharmacopeia
(Nasdaq: PCOP ), an innovator in the discovery and development of novel
small molecule therapeutics, announced today that results from the
company's Phase 2a clinical trial evaluating PS433540, its first-in-class
Dual Acting Rec...
Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
SAN FRANCISCO, April 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics
(Nasdaq: NKTR ) announced today that positive preclinical and clinical
results for its pipeline programs will be presented at numerous medical and
scientific meetings over the coming months. These presentations will
Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
NEW BRUNSWICK, N.J., April 2, 2008 /PRNewswire-FirstCall/ -- Senesco
Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT ) announced today
that Dr. Raghavendra Mirmira, one of the Company's funded researchers, will
be presenting his findings regarding preclinical pancreatic islet cell ...
CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
BRANFORD, Conn., Nov. 26 /PRNewswire-FirstCall/ -- CuraGen Corporation
(Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on
oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced
today that updated preliminary clinical trial results from the Phase II
IDM Pharma Announces Upcoming Clinical Data Presentations
IRVINE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
(Nasdaq: IDMI ), a biotechnology company focused on the development of
innovative cancer therapies, today announced details on clinical data
presentations evaluating three of the Company's pipeline compounds to be
Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar
Therapeutics (Nasdaq: NKTR ) announced today that preclinical data for its
proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented
at the upcoming
AACR-NCI-EORTC International Conference on Molecular
Targets and Th...
Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals,
Inc. (Nasdaq: ARNA ) announced today that the company is scheduled to
provide a corporate overview of its clinical development and discovery
programs at four upcoming
investor conferences: -- ThinkEquity Partners' 5th Annua...
ViroPharma to Present at Three Upcoming Healthcare Conferences
EXTON, Pa., Aug. 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated
(Nasdaq: VPHM ) today announced that Vincent Milano, vice-president, chief
operating officer and chief financial officer of ViroPharma, will present
at the Thomas Weisel Partners 2007 Healthcare Conference at 8:00 A.M. ET o...
New Clinical Data for Cytogen's Quadramet and Prostacint to be
Reported at Upcoming Major Medical Meetings
PRINCETON, N.J.--(BUSINESS WIRE)--Mar 26, 2007 - Cytogen
Corporation (NASDAQ: CYTO) today announced that five abstracts will
be presented or published at upcoming
major medical meetings. The
data will include various Phase 1 clinical results for QUADRAMET(R)
(samarium Sm-153 lexidronam injection) i...
Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
HAYWARD, Calif., April 10, 2007 /PRNewswire-FirstCall/ -- Kosan
Biosciences Incorporated announced data will be presented on the
Company's clinical and preclinical pipeline, including its Hsp90
inhibitor, epothilone and nuclear export inhibitor programs, at the
2007 Annual Meeting of the American ...
CombinatoRx to Present Combination High Throughput Screening (cHTS)
Data at Upcoming AACR Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - CombinatoRx,
Incorporated (NASDAQ: CRXX), today announced that posters related
to its oncology research efforts will be presented at the 98th
Annual Meeting of the American Association for Cancer Research,
April 14-18, 2007 in Los Angeles, CA.
Othera Pharmaceuticals Announces Upcoming Presentation Based Upon
Expanded Understanding of Lead Compound Mechanism of Action
EXTON, Pa.--(BUSINESS WIRE)--Apr 19, 2007 - Othera Pharmaceuticals,
Inc. today announced that Dr. Shaker Mousa, Professor of
Pharmacology and Executive Vice President and Chairman of the
Pharmaceutical Research Institute at Albany College of Pharmacy,
will present new preclinical data detailing the...
CuraGen and TopoTarget Announce New Clinical Results With
Belinostat to be Reported at Upcoming Major Medical Meetings
BRANFORD, Conn., April 19, 2007 /PRNewswire-FirstCall/ --
CuraGen Corporation and TopoTarget A/S announced today that
preliminary interim clinical data on intravenous belinostat
(PXD101), a histone deacetylase (HDAC) inhibitor being investigated
for the treatment of cancer, are expected to be pres...
FDA Announces Change of Location Notice for Upcoming Advisory
ROCKVILLE, Md., April 18, 2007--Due to water damage caused by
flooding over the weekend, FDA has been forced to change the
location for the upcoming
Antiviral Drugs Advisory Committee
meeting on April 24, 2007 to discuss new drug application for
maraviroc 300 milligram tablets. Originally schedule...
Introgen and Clinical Collaborators to Report New Results with
Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
AUSTIN, Texas--(BUSINESS WIRE)--May 29, 2007 - Introgen
Therapeutics, Inc. (NASDAQ:INGN) and the Company's clinical
collaborators will report updated Phase 2 clinical trial results
for its lead cancer therapy product candidates at the upcoming
annual meetings of The American Society of Clinical Onc...
Novel Mechanism Insights and Additional Data on CombinatoRx Drug
Candidates to Be Presented at Upcoming EULAR Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - CombinatoRx,
Incorporated (NASDAQ: CRXX), today announced that data from its
randomized, blinded, placebo-controlled phase 2 clinical trials of
CRx-102 in patients with osteoarthritis (OA) and rheumatoid
arthritis (RA) will be featured at the Europea...
Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Nymox
Pharmaceutical Corporation (NASDAQ: NYMX) today announced that
detailed results from the Company's recently completed studies of
NX-1207 for benign prostatic hyperplasia (BPH) will be presented at
a series of upcoming
U.S. urology meeti...
Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.
HASBROUCK HEIGHTS, NJ (June 21, 2007) Nymox Pharmaceutical
Corporation (NASDAQ: NYMX) today announced that detailed results
from the Company’s recently completed studies of NX-1207 for
benign prostatic hyperplasia (BPH) will be presented at a series of
upcoming U.S. urology meetings, beginni...
Keryx Biopharmaceuticals, Inc. Announces Poster Presentations
Highlighting Mechanism of Action and Clinical Activity of
Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American
Diabetes Association 67th Scientific Sessions in Chicago, Illinois
NEW YORK, June 22, 2007 /PRNewswire-FirstCall/ -- Keryx
Biopharmaceuticals, Inc. today announced that abstracts related to
Sulonex(TM) (sulodexide oral gelcap) have been selected for
publication or presentation during the poster sessions scheduled to
take place at the upcoming
American Diabetes As...
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
...ontaining activating KRAS mutations."
Detailed efficacy and safety data according to KRAS status will be submitted for presentation at an upcoming
PRIME ( P anitumumab R andomized trial I n combination with chemotherapy for M etastatic colorec...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
... us to continue to advance the technology and fill the pipeline with more exciting new drugs," said B. Lynne Parshall, COO and CFO of Isis.
Report full data from a Phase 3 study evaluating mipomersen in homozygous Familial Hypercholesterolemia (FH) patients; p...
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
...lf that of Forteo(R) in the highest dose of BA058 tested. Radius will submit additional detailed results from the Phase 2 study for presentation at an upcoming
"The results of this study affirm BA058's safety and bone-building activity and support its promise as a next-generation anabo...
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
...t in a number of serious bone complications, collectively called SREs.
Full safety and efficacy data will be submitted for presentation at an upcoming
medical meeting in the second half of this year.
This was an international Phase 3, randomized, doubleblind, active controlle...
John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden
...at artists to come together to powerfully and effectively fight AIDS in Africa," said Legend. "I'm proud to be partnering with Gap and (RED)(TM) on my upcoming
Madison Square Garden concert, because I know the money generated will go directly to help get medicine to those who need it."
Tickets to this ...
BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
...es of the study data, including secondary efficacy endpoints and detailed safety is underway. Additional data will be submitted for presentation at an upcoming
"The clinical outcomes of these Phase 3 studies are important, especially during the declared influenza pandemic, as they ...
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
...esult in a number of serious bone complications, collectively called SREs.
Full efficacy and safety data will be submitted for presentation at an upcoming
medical meeting in the second half of this year.
This was an international Phase 3, randomized, double-blind study comparing d...
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
...model of aggressive arthritis.
These data were published in the June 14, 2009 online edition of Nature Medicine and will be published in the upcoming
July 2009 print edition in an article titled: A Selective Inhibitor of the Immunoproteasome Subunit LMP7 Blocks Cytokine Production and Attenuates Pr...
Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
... biomedical, health care and life science professionals from all
over the world," said Nadav Kidron, Oramed CEO.
For more information about the upcoming
ILSI Biomed conference, please
About Oramed Pharmaceuticals
Oramed Pharmaceuticals ...
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
...and the FDA reached agreement on the design of the upcoming
Phase 3 study via the Special Protocol Assessment ...data from the prior Phase 3 study of orBec(R), the upcoming
confirmatory Phase 3 clinical trial will be a high...response from the EMEA regarding the design of our upcoming
confirmatory, pivotal Phase 3 study," stated Chris...
SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine
Since the BARI-2D study enrolled a very small subset of CAD patients with diabetes, SCAI looks forward to additional data from the upcoming
FREEDOM trial, which may shed more light on revascularization options for this growing patient population.
What BARI-2D Demonstrates About Pat...
Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
...actory Angina Due to Diffuse Coronary Heart Disease", reinforce the company's regulatory strategy of submitting an IDE for its PHOENIX System in the upcoming
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the therapies for the treatment of chroni...
Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
... factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.
Members of the media are welcome to attend our upcoming
webinar entitled Hospital Anti-Infectives Insight Series: Analyzing Prescribing Trends and Emerging Therapies in the Hospital Antibiotic Market. T...
VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
...uding results from two phase 3 obesity trials of our lead product Qnexa as well as data from the REVIVE trial of avanafil and participation in several upcoming
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet...
HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials
...ich was reviewed and approved by the leadership of the five networks, recommending the use of the Abbott RealTi m e HIV-1 assay and m 2000 system for upcoming
clinical trials in 2009 and beyond that have a primary focus on viral load measurements. The recommendation applies to testing performed at adult and ...